Samsung Bioepis Pushes Stelara Rival Into Phase I

Proposed Ustekinumab Biosimilar Is Competing With Several Other Candidates

Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.

Phase One 1 Blocks
Samsung Bioepis’ SB17 ustekinumab biosimilar has started Phase I trials • Source: Shutterstock

The Samsung Bioepis joint venture between Biogen and Samsung Biologics has announced that its SB17 proposed biosimilar rival to Janssen’s Stelara (ustekinumab) has moved into Phase I trials.

The randomized, double-blind, three-arm, parallel, single-dose study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Stelara and SB17 in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.